Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at blood and tissue samples from patients with prostate cancer receiving androgen deprivation therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cancer Research UK
• Treatments: Androgen Antagonists; Androgens; Hormones

Criteria

DISEASE CHARACTERISTICS:

• Meets 1 of the following criteria:

• High clinical suspicion of prostate cancer, based on an abnormal digital rectal examination and PSA (> 20 ng/mL)

• Newly diagnosed, castration-resistant prostate cancer

• Clinical stage ≥ T2c disease

• Significant tumor volume on initial diagnostic biopsy (> 50% of cores)

• Likely to receive androgen deprivation therapy for prostate cancer

PATIENT CHARACTERISTICS:

• No contraindication to transrectal needle biopsy

• No contraindication to MRI or prostate needle biopsy

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics